SWIZGLIPT-M

This brand name is authorized in Nigeria.

Active ingredients

The drug SWIZGLIPT-M contains a combination of these active pharmaceutical ingredients (APIs):

1	Metformin UNII 786Z46389E - METFORMIN HYDROCHLORIDE
	Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.
	Read more about Metformin
2	Sitagliptin UNII QFP0P1DV7Z - SITAGLIPTIN
	Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors. The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones.
	Read more about Sitagliptin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-7893	Tablet	SWIZGLIPT-M TABLETS TAB 500 mg; 50 mg 1 X 10	83 RNW-PP-270038 SWIZGLIPT-M TABLETS SITAGLIPTIN/METFORMIN HYDROCHLORIDE USP 50MG/500MG Sitagliptin Phosphate Monohydrate 64.25mg, Metformin hydrochloride USP 50mg, Microcrystalline cellulose pH 102 24.5mg, Povidone K 30 40.8mg, Sodium Lauryl Sulfate 3.05mg, Purified Water q.s, Croscarmellose Sodium 5mg, Sodium Stearyl fumerate 12.4mg, Opadry White 21K 58794 17.5mg, Isopropyl Alcohol q.s, Iron Oxide Red 0.163mg, Iron Oxide Yellow 0.813mg Dichloromethane q.s. B4-7893 Drugs ALIMENTARY TRACT AND METABOLISM Imported Products 110 POM 2 9/29/2022 HEALTHLINE LIMITED, 29,ADENIYI JONES IKEJA LAGOS 7081123545 healthline.ng@gmail.com M/S SWISS GARNIER LIFE SCIENCES., 21-23, INDUSTRIAL AREA, MEHATPUR, DISTT, UNA (H.P.) -174315, INDIA., India	28/03/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BD07	Metformin and sitagliptin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-7893